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Lymphangioleiomyomatosis (LAM) is a rare disease that affects women, especially in child-bear- 
ing age. Clinical manifestations include angiomyolipoma, pneumothorax, chylothorax, cystic chan- 
ges of lungs and progressive pulmonary failure. In this article, we report a case of lung transplan-
tation (LuTX) for end stage pulmonary LAM and the treatment of angiomyolipoma showing growth 








Lymphangioleiomyiomatosis (LAM) is a multisystem disease occurring in lung, abdomen and axial lymphatics 
[1]. This disease is rare—its prevalence is 1 in 1,000,000 in the whole population—and it usually affects young 
women. LAM has two types: sporadic LAM and cases associated with the genetic disease tuberous sclerosis [2]. 
Tuberous sclerosis is caused by the mutations of genes TSC1 and TSC2 which regulate the proteins hamartin and 
tuberin. These proteins regulate their signal by means of mammalian target of rapamycin (mTOR) which con-




trols cell size and growth [3]. LAM has many similarities to cancer including inappropriate cell growth and sur-
vival, infiltration of surrounding tissues, metastasis formation via blood and lymphatic circulation. LAM can be 
considered as an elegant, monogenic model of neoplasia which be categorized as benign or malignant [4]. Pul-
monary manifestations of LAM include pneumothorax—at least two thirds of all patients—chylothorax and cys-
tic changes of the lung which results in progressive decline in pulmonary function. In the advanced phases of the 
disease the last therapeutic option is lung transplantation (LuTX) [5]. Angiomyolipomas belong to the extra-
pulmonary manifestations of LAM. In most cases, angiomyolipomas involve the axial lymphatics in the upper 
retroperitoneum (RP). 
2. Case Report 
A 42-year-old woman developed progressive exercise induced dyspnea in 2008. Spirometry confirmed partially 
reversible obstructive ventilatory disorder and initial treatment with inhaled corticosteroid plus long acting β2 
receptor agonist was introduced. Despite treatment dyspnea progressed and lung function declined. In 2010 
chest CT confirmed cystic pulmonary changes with fibrosis and emphysema, abdominal and inguinal lymph 
node enlargement. Subsequently surgical lung biopsy was performed and histology confirmed changes typical 
for LAM. Deteriorating progression of pulmonary function and recurring pneumothorax led to intensive care 
unit treatment in March 2011 requiring mechanical ventilation. Due to end stage lung disease she was presented 
at the LuTX committee and was listed for LuTX (lung functional values before transplantation: FVC 2.30 L 
(68% predicted), FEV1: 0.93 L (32% predicted), FEV1/FVC: 40%).  
Bilateral LuTX was performed in Vienna in January 2012. Postoperatively she received triple immunosup-
pressive therapy including tacrolimus, mycophenolate mofetil and prednisolon. After two weeks surveillance 
bronchoscopy confirmed A2B1-2 rejection, following steroid shot treatment control transbronchial lung biopsy 
was negative for rejection (A0B0). Lung function has been gradually improving. The six-month chest-abdo- 
minal CT scan showed an enlargement in the angiomyolipoma located in the upper RP (Figure 1(a)) compared 
to the preoperative state. In October 2012, 9 months after TX everolimus (plasma level: 2.31 ng/ml) was added 
to tacrolimus (plasma level: 7.7 ng/ml) therapy, while combination with mycophenolate mofetil and prednisolon 
maintained. Six month after the introduction of combination therapy with mTOR inhibitor the angiomyolipoma 
was not detectable on the one year chest-abdominal CT (Figure 1(b)). The patient is since on everolimus, tacro-
limus, mycophenolate mofetil and prednisolon therapy with the same plasma level as the combined therapy 
started, showing excellent graft function (lung functional values October 2014: FVC 3.63 L (110% predicted), 
FEV1: 2.59 L (91% predicted), FEV1/FVC: 71%), and no signs of abdominal disease on the abdominal CT scan 
performed 2 years after LuTX. 
3. Discussion 
LAM is a rare cause of respiratory failure requiring LuTX in young women. Angiomyolipoma is commonly ob-
served and specific treatment of the disease is still unavailable. Angiomyolipomas with a diameter < 4 cm are at  
 
 
Figure 1. (a) Abdominal angiomyolipoma in LAM patient 6 months after LuTX; (b) Complete 
remission of angiomyolipoma in LAM patient after 6 month of treatment with everolimus- 
tacrolimus combination therapy.                                                    




a low risk of progression and ultrasound follow-ups are sufficient every 1 or 2 years. In our case the angiomyo-
lipoma was asymptomatic, however due to its extent (102 mm) surgical removal might be suggested due the 
possibility of life-threatening haemorrhage [2]. This benign tumor could not be removed surgically as LAM is a 
multisystem disease and intervention would not have stopped the development of angiomyolipomas at subse-
quent sites. Although the tumors have oestrogen and progesterone receptors there is no firm evidence of efficacy 
of hormone treatment in this disease [2]. A comprehensive study examined the effects of the mTOR inhibitor 
sirolimus on angiomyolipomas. A 12 month treatment with sirolimus led to significant reduction (53.2% ± 
26.6%, p < 0.001) within a group of 25 patients in a phase II study [6]. The efficacy of sirolimus is the result of 
the known pathomechanism of LAM: tuber in and hamartin proteins are responsible for inhibiting mTOR com-
plex which regulates cell growth. Without this inhibiting signal cell proliferation pathway is uncontrolled [7]. 
Based on these results and experiences with everolimus in lung transplantation we decided to start treatment 
with a combination of tacrolimus and everolimus. CT performed 6 months after the combination therapy re-
sulted in complete remission of RP angiomyolipoma. In a previous case report the treatment of angiomyolipoma 
in LAM patient receiving LuTX included combination therapy of everolimus with cyclosporine, mycophenola-
temofetil and steroids. This treatment resulted in a reduction of angiomyolipoma by ~30% after 6 months of 
treatment [7]. The difference between the effects of cyclosporin and tacrolimus might have a significant impact 
of everolimus on angiomyolipoma cells. 
4. Conclusion 
In our LAM patient requiring lung transplantation, the combined use of everolimus plus tacrolimus resulted in 
complete remission of the angiomyolipoma 6 months after treatment without influencing perfect graft function. 
According to our results using everolimus and tacrolimus combination in LAM, it is considered to be an ade-
quate and safe way of significantly reducing or even reaching full remission of angiomyolipomas after LuTX in 
these patients. 
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